These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31221700)

  • 21. Overnight closed-loop insulin delivery in young people with type 1 diabetes: a free-living, randomized clinical trial.
    Hovorka R; Elleri D; Thabit H; Allen JM; Leelarathna L; El-Khairi R; Kumareswaran K; Caldwell K; Calhoun P; Kollman C; Murphy HR; Acerini CL; Wilinska ME; Nodale M; Dunger DB
    Diabetes Care; 2014; 37(5):1204-11. PubMed ID: 24757227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Closing the Loop on Managing Youth With Type 1 Diabetes: Children Are Not Just Small Adults.
    Sherr JL
    Diabetes Care; 2018 Aug; 41(8):1572-1578. PubMed ID: 29936422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The "Glucositter" overnight automated closed loop system for type 1 diabetes: a randomized crossover trial.
    Nimri R; Danne T; Kordonouri O; Atlas E; Bratina N; Biester T; Avbelj M; Miller S; Muller I; Phillip M; Battelino T
    Pediatr Diabetes; 2013 May; 14(3):159-67. PubMed ID: 23448393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized Controlled Trial of Mobile Closed-Loop Control.
    Kovatchev B; Anderson SM; Raghinaru D; Kudva YC; Laffel LM; Levy C; Pinsker JE; Wadwa RP; Buckingham B; Doyle FJ; Brown SA; Church MM; Dadlani V; Dassau E; Ekhlaspour L; Forlenza GP; Isganaitis E; Lam DW; Lum J; Beck RW;
    Diabetes Care; 2020 Mar; 43(3):607-615. PubMed ID: 31937608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System.
    Messer LH; Forlenza GP; Sherr JL; Wadwa RP; Buckingham BA; Weinzimer SA; Maahs DM; Slover RH
    Diabetes Care; 2018 Apr; 41(4):789-796. PubMed ID: 29444895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Afrezza on Glucose Dynamics During HCL Treatment.
    Galderisi A; Cohen N; Calhoun P; Kraemer K; Breton M; Weinzimer S; Cengiz E
    Diabetes Care; 2020 Sep; 43(9):2146-2152. PubMed ID: 32661108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Day and night home closed-loop insulin delivery in adults with type 1 diabetes: three-center randomized crossover study.
    Leelarathna L; Dellweg S; Mader JK; Allen JM; Benesch C; Doll W; Ellmerer M; Hartnell S; Heinemann L; Kojzar H; Michalewski L; Nodale M; Thabit H; Wilinska ME; Pieber TR; Arnolds S; Evans ML; Hovorka R;
    Diabetes Care; 2014 Jul; 37(7):1931-7. PubMed ID: 24963110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized Outpatient Trial of Single- and Dual-Hormone Closed-Loop Systems That Adapt to Exercise Using Wearable Sensors.
    Castle JR; El Youssef J; Wilson LM; Reddy R; Resalat N; Branigan D; Ramsey K; Leitschuh J; Rajhbeharrysingh U; Senf B; Sugerman SM; Gabo V; Jacobs PG
    Diabetes Care; 2018 Jul; 41(7):1471-1477. PubMed ID: 29752345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MD-Logic overnight type 1 diabetes control in home settings: A multicentre, multinational, single blind randomized trial.
    Nimri R; Bratina N; Kordonouri O; Avbelj Stefanija M; Fath M; Biester T; Muller I; Atlas E; Miller S; Fogel A; Phillip M; Danne T; Battelino T
    Diabetes Obes Metab; 2017 Apr; 19(4):553-561. PubMed ID: 27981804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DREAM5: An open-label, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control by comparing the MD-Logic automated insulin delivery system to sensor augmented pump therapy in patients with type 1 diabetes at home.
    Biester T; Nir J; Remus K; Farfel A; Muller I; Biester S; Atlas E; Dovc K; Bratina N; Kordonouri O; Battelino T; Philip M; Danne T; Nimri R
    Diabetes Obes Metab; 2019 Apr; 21(4):822-828. PubMed ID: 30478937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meta-analysis of overnight closed-loop randomized studies in children and adults with type 1 diabetes: the Cambridge cohort.
    Kumareswaran K; Elleri D; Allen JM; Harris J; Xing D; Kollman C; Nodale M; Murphy HR; Amiel SA; Heller SR; Wilinska ME; Acerini CL; Evans ML; Dunger DB; Hovorka R
    J Diabetes Sci Technol; 2011 Nov; 5(6):1352-62. PubMed ID: 22226252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, efficacy and glucose turnover of reduced prandial boluses during closed-loop therapy in adolescents with type 1 diabetes: a randomized clinical trial.
    Elleri D; Biagioni M; Allen JM; Kumareswaran K; Leelarathna L; Caldwell K; Nodale M; Wilinska ME; Haidar A; Calhoun P; Kollman C; Jackson NC; Umpleby AM; Acerini CL; Dunger DB; Hovorka R
    Diabetes Obes Metab; 2015 Dec; 17(12):1173-9. PubMed ID: 26257323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes.
    Petrovski G; Al Khalaf F; Campbell J; Umer F; Almajaly D; Hamdan M; Hussain K
    Acta Diabetol; 2021 Feb; 58(2):207-213. PubMed ID: 33044604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Participants' Experiences of, and Views About, Daytime Use of a Day-and-Night Hybrid Closed-Loop System in Real Life Settings: Longitudinal Qualitative Study.
    Lawton J; Blackburn M; Rankin D; Allen JM; Campbell FM; Leelarathna L; Tauschmann M; Thabit H; Wilinska ME; Elleri D; Hovorka R
    Diabetes Technol Ther; 2019 Mar; 21(3):119-127. PubMed ID: 30720338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Closed-loop insulin delivery systems in children and adolescents with type 1 diabetes.
    Dovc K; Battelino T
    Expert Opin Drug Deliv; 2020 Feb; 17(2):157-166. PubMed ID: 32077342
    [No Abstract]   [Full Text] [Related]  

  • 36. Day-to-day variability of insulin requirements in the inpatient setting: Observations during fully closed-loop insulin delivery.
    Boughton CK; Daly A; Thabit H; Hartnell S; Herzig D; Vogt A; Ruan Y; Wilinska ME; Evans ML; Coll AP; Bally L; Hovorka R
    Diabetes Obes Metab; 2021 Aug; 23(8):1978-1982. PubMed ID: 33822461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies.
    Hovorka R; Kumareswaran K; Harris J; Allen JM; Elleri D; Xing D; Kollman C; Nodale M; Murphy HR; Dunger DB; Amiel SA; Heller SR; Wilinska ME; Evans ML
    BMJ; 2011 Apr; 342():d1855. PubMed ID: 21493665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New closed-loop insulin systems.
    Boughton CK; Hovorka R
    Diabetologia; 2021 May; 64(5):1007-1015. PubMed ID: 33550442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First Look at Control-IQ: A New-Generation Automated Insulin Delivery System.
    Brown S; Raghinaru D; Emory E; Kovatchev B
    Diabetes Care; 2018 Dec; 41(12):2634-2636. PubMed ID: 30305346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is an artificial pancreas (closed-loop system) for Type 1 diabetes effective?
    Boughton CK; Hovorka R
    Diabet Med; 2019 Mar; 36(3):279-286. PubMed ID: 30183096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.